Date of event
Thursday, September 9, 2021 - 9:00 am -
Saturday, September 11, 2021 - 5:00 pm
Add to Calendar 2021-09-09 09:00:00 2021-09-11 17:00:00 COLDA 2021: Conference On Liver Disease in Africa AASLD alonzo.tolver@boldrstrategy.com America/New_York public

Discount code for 25% discount for all our members: ENDORSER25


 

COLDA 2021

Organized by the SHARE Global Health Foundation in close collaboration with regional societies, COLDA 2021 aims at empowering healthcare professionals (HCPs) to diagnose, prevent, treat and achieve a cure for liver diseases for the benefit of patients in Africa. This being the 4th COLDA, COLDA continues to cultivate a platform that provides a unique opportunity for clinicians, researchers, policymakers, industry representatives, and other healthcare professionals in the African region. Together with support from an international community of experts, they will exchange knowledge on the latest developments and achievements in the management of viral hepatitis and liver disease with a special focus on the African context.

AASLD Members - COLDA Speakers

 

Session Title: AASLD - Future Partnership Opportunities

Date: Friday, 10 September 2021  |  4:20 - 5:00 pm (local South African Time)   

 

Speakers: 

 

Raymond Chung, MD, FAASLD

Dr. Raymond Chung is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at Massachusetts General Hospital. He is also Professor of Medicine at Harvard Medical School. He has been an internationally recognized leader in HCV research in the areas of virology and pathogenesis, including hepatocarcinogenesis. He directs the NIH Cooperative Center for Human Immunology and is co-PI of the Harvard HBV Consortium of the NIH HBV Research Network. He is PI of the MGH GI Division’s T32 Training Grant and holds several NIH R01 grants. He has been an Associate Editor of Hepatology, Gastroenterology, and the Journal of Infectious Diseases, and is currently President of the American Association for the Study of Liver Diseases (AASLD). He has served as co-Chair of the AASLD/IDSA HCV Guidance panel charged with issuing treatment recommendations for hepatitis C. He also served as Co-Chair of the 24th International Symposium on HCV in 2017. He has authored more than 500 original articles, reviews, and editorials.

Raymond Chung, MD, FAASLD


 

Kidist Yimam, MD

Dr. Kidist K. Yimam is a Transplant Hepatologist and the Medical Director of California Pacific Medical Center (CPMC), San Francisco, CA, Autoimmune Liver Disease (AILD) Program. She is also the Director of CPMC’s Cholangiocarcinoma Program, Director of the Autoimmune Liver Disease Research Fellowship and serves as a Research Advisor for the Internal Medicine Residency Program. She is a founding member of the North America Consortium for Autoimmune Liver Diseases (CALiD) and has served as a member of its steering committee. Dr. Yimam is engaged in efforts in promoting healthcare equality locally and nationally in collaboration with the American Liver Foundation where she serves as a member of its medical advisory board.  She is involved in promoting Women’s Health and has served as American Association for the Study of Liver Diseases (AALSD)’s Women Health Representative for the last 3 years with significant contributions including the formation of the first Women’s Health in Liver Diseases Program at The Liver Meeting which has now become a recurring yearly event at the Liver Meeting main forum. She currently serves as a member of AASLD’s Global Health Outreach and Engagement Committee, and a member of its sub-Saharan Africa working group. Dr. Yimam is dedicated to promoting AASLD’s engagement and collaboration with colleagues in Africa to promote research, education, and improved patient care in the region.

Kidist Yimam, MD


 

Lewis Roberts, MBChB, PhD, FAASLD

Dr. Lewis R. Roberts is the Peter and Frances Georgeson Professor in Gastroenterology Cancer Research and Consultant in Gastroenterology and Hepatology at the Mayo Clinic, where he is Co-Principal Investigator of the Mayo Specialized Program of Research Excellence (SPORE) in Hepatobiliary Cancers. His research focuses on molecular mechanisms of liver and biliary carcinogenesis; biomarkers for diagnosis of liver, bile duct and pancreas cancers; and prevention, diagnosis and treatment of hepatitis and liver cancer, with a particular interest in immigrant African communities in the USA as well as in Africa. He has authored over 400 articles, book chapters and letters, and co-edited the book “Evaluation and Management of Liver Masses”. He serves as President of Africa Partners Medical, a non-profit organization focused on improving healthcare delivery in Africa through medical education, practical skills training, provision of medical equipment and supplies, and health advocacy; as President of the West Africa Institute for Liver and Digestive Diseases Foundation; and as a member of the Advisory Council for The Hepatitis Fund. Dr. Roberts is also a founding member of the Africa HepatoPancreatoBiliary Cancer Consortium.

Lewis Roberts, MBChB, PhD, FAASLD


 

Gyongi Szabo, MD, PhD, FAASLD

Gyongyi Szabo, MD, PhD is and the Mitchell T. Rabkin, M.D. Chair, Professor of Medicine and Faculty Dean at Harvard Medical School and Chief Academic Officer at the Beth Israel Deaconess Medical Center and Beth Israel Lahey Health. In this role, she leads all basic, translational, and clinical research activities, innovation, education, and faculty development for the BIDMC, a Harvard teaching hospital and for BILH, the second largest health care system in New England.

A physician scientist and an internationally known expert in liver immunology and inflammation Dr. Szabo investigates the complex role of chronic inflammation in progression of liver diseases. Her laboratory studies the cellular and molecular mechanisms of inflammation and innate immunity in liver injury to identify therapeutic targets focused on non-alcoholic liver disease, NASH, and alcoholic liver disease. Her investigations recently revealed the importance of micro-RNAs and extracellular vesicles in liver diseases. She showed that exosomes cannot only be biomarkers but also vehicles of inter-cellular and inter-organ communication. Her studies identified microRNA-122 as a central player in steatohepatitis and showed that miR-155 regulates exosome release. Earlier, her group discovered that Interferon Regulatory Factor 3 downstream from Toll-like receptor 4 regulates hepatocellular damage and represents a key molecule in alcoholic hepatitis. Dr. Szabo’s group made the novel discovery that NLRP3 activation and the IL-1ß pathway are potential therapeutic targets in alcoholic hepatitis and NASH. Her translational studies with the use of IL-1 receptor antagonist in a preclinical model of alcoholic hepatitis provided basis for a subsequent first-time clinical trial in alcoholic hepatitis with IL-1 inhibition. She is the lead investigator on the AlcHeptNet NIH-supported multicenter clinical trial in alcoholic hepatitis. Dr. Szabo’s is member of the Hungarian Academy of Sciences, and fellow of the AASLD, AGA and the American College of Physicians (ACP). Dr. Szabo serves on advisory boards of several federal agencies, leading academic institutions, and pharmaceutical companies. Dr. Szabo served on the Governing Board and as President of the American Association for the Study of Liver Diseases (AASLD) in 2015 and she is the inaugural Editor-in-Chief of Hepatology Communications.

Gyongi Szabo, MD, PhD, FAASLD


 

W. Ray Kim, MD, FAASLD

W. Ray Kim, MD is Professor and Chief in the Division of Digestive Health at Stanford University School of Medicine.  Dr. Kim earned his medical diploma at Seoul National University and received his GI and transplant hepatology training at Mayo Clinic. 

Dr. Kim’s research interest has been in outcomes modeling in liver disease.  His research accomplishments include development of the Model for End Stage Liver Disease (MELD) score.  His research has produced > 250 publications to date with an h-index of > 70.

Dr. Kim serves on the Governing Board of AASLD as a Councilor currently and is elected to be President in 2024.

W. Ray Kim, MD, FAASLD


 

Staff:  Dominque Clayton, MBA

Dominique Clayton, MBA is the manager, online education at the American Association for the Study of Liver Diseases. She graduated from the University of Louisiana at Lafayette with a Bachelor of Science in business administration (marketing) and a master’s in business administration with an emphasis in health systems management from Texas Woman’s University. In her role, she provides professional development and continuing education for medical professionals through various eLearning activities and serves as the lead LMS administrator.

Dominique sits on two nonprofit boards in Washington, DC and Baltimore, MD. The organizations are serving domestic and sexual abuse survivors and youth mentoring programs. She is a member of the alumni associations for the University of Louisiana at Lafayette and Texas Woman’s University, National Black MBA Association, Sigma Gamma Rho Sorority, Incorporated and American Society of Association Executives. In her spare time, she continues to advocate for mental health, freelance as a writer and volunteering for causes that are important to her. She resides in Northern Virginia.


 

Dominque Clayton, MBA


 

To learn more, visit the meeting website.

This meeting is endorsed by AASLD